Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the effect of ranolazine compared to placebo on the average weekly
angina frequency in subjects with chronic stable angina and coronary artery disease (CAD) who
have a history of type 2 diabetes mellitus (T2DM), and whether ranolazine can reduce the
frequency of angina (chest pain) attacks, compared to a placebo. Subjects will be asked to
record their daily angina episodes in a diary at the end of each study day. Ranolazine is
approved for the treatment of chronic angina, and is not approved for the treatment of T2DM.